{"title":"呼吸道合胞病毒预防的快速变化的景观。","authors":"Joan L Robinson, Jesse Papenburg","doi":"10.3138/jammi-2023-05-31","DOIUrl":null,"url":null,"abstract":"<p><p>The introduction of nirsevimab (a respiratory syncytial virus [RSV] monoclonal antibody that can protect for minimum 5 months with a single dose) and RSV maternal vaccines to protect young infants has the potential to dramatically decrease RSV hospitalizations in Canada. However, there remain many unanswered questions before optimal use of these products can be assured.</p>","PeriodicalId":36782,"journal":{"name":"JAMMI","volume":"8 3","pages":"165-171"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697103/pdf/","citationCount":"0","resultStr":"{\"title\":\"The rapidly changing landscape of respiratory syncytial virus prophylaxis.\",\"authors\":\"Joan L Robinson, Jesse Papenburg\",\"doi\":\"10.3138/jammi-2023-05-31\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The introduction of nirsevimab (a respiratory syncytial virus [RSV] monoclonal antibody that can protect for minimum 5 months with a single dose) and RSV maternal vaccines to protect young infants has the potential to dramatically decrease RSV hospitalizations in Canada. However, there remain many unanswered questions before optimal use of these products can be assured.</p>\",\"PeriodicalId\":36782,\"journal\":{\"name\":\"JAMMI\",\"volume\":\"8 3\",\"pages\":\"165-171\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697103/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAMMI\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3138/jammi-2023-05-31\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMMI","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3138/jammi-2023-05-31","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
The rapidly changing landscape of respiratory syncytial virus prophylaxis.
The introduction of nirsevimab (a respiratory syncytial virus [RSV] monoclonal antibody that can protect for minimum 5 months with a single dose) and RSV maternal vaccines to protect young infants has the potential to dramatically decrease RSV hospitalizations in Canada. However, there remain many unanswered questions before optimal use of these products can be assured.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
